ClinicalTrials.gg
Not yet recruitingNCT07208656Updated Dec 4, 2025

The Impact of Medical TV Drama in Improving Literacy on Neurocysticercosis

An interventional study of Medical TV Drama Episode (House M.D.) in Neurocysticercosis, Health Literacy and Epilepsy, sponsored by Cephas Health Research Initiative Inc, Ibadan, Nigeria. Not yet recruiting. Open to participants aged 18 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-04.

Sponsored by Cephas Health Research Initiative Inc, Ibadan, Nigeria · Not applicable, Interventional, and Prevention

From the registry’s dates

  • Primary completion was expected by Feb 2026, 8 months ago, but the record still lists the study as not yet recruiting.
Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 35 Years
Sex
All
01

Study summary

This randomized controlled trial evaluates whether exposure to a medical television drama improves knowledge of neurocysticercosis (NCC) among young adults. Sixty participants aged 18-35 will be randomly assigned to either an intervention group, which will watch a medically relevant TV episode (House M.D., Season 1, Episode 1), or a control group with no media exposure. Both groups will complete pre- and post-test questionnaires assessing knowledge of NCC. The primary outcome is change in NCC-related knowledge. Secondary outcomes include motivation to seek further health information and perceived credibility of the media source

Read the detailed description

Neurocysticercosis (NCC) is a parasitic infection of the central nervous system caused by the larval stage of Taenia solium, the pork tapeworm. It is one of the leading preventable causes of epilepsy worldwide, particularly in low- and middle-income countries (LMICs). Despite this, awareness and understanding of NCC remain low among young adults, who often play a key role in disseminating health information within their families and communities. Conventional health education efforts have had limited success in increasing public literacy about NCC, underscoring the need for innovative, engaging communication strategies.

This study uses an open-label, two-arm randomized controlled trial design to evaluate whether exposure to a medical television drama can improve knowledge of NCC among young adults. The trial will be conducted entirely online to enable participation from a geographically diverse population and to reflect modern media consumption patterns. After providing electronic informed consent, eligible participants will be randomly assigned to either an intervention or control group in a 1:1 ratio using a computer-generated allocation process to ensure randomization integrity.

Participants in the intervention group will watch House M.D., Season 1, Episode 1 - a medically themed television episode featuring a dramatized case of parasitic brain infection with conceptual relevance to NCC. The control group will not view the episode during the study period but will be offered access to the same content after data collection is complete. Both groups will complete structured online questionnaires before and after the intervention period to measure changes in NCC-related knowledge and attitudes. These questionnaires have been developed and validated through expert review and pilot testing.

The trial's primary objective is to determine whether viewing the medical TV drama improves knowledge of NCC, as measured by changes in pre- and post-intervention knowledge scores. Secondary objectives include assessing participants' motivation to learn more about NCC and their perception of the credibility of the TV drama as an educational resource. Statistical analyses will include paired and independent t-tests (or corresponding non-parametric tests where appropriate), with significance set at p \< 0.05.

Data will be collected securely using encrypted online survey platforms. All responses will be anonymized, and no personally identifiable information will be stored. Data access will be limited to the research team, and all procedures will comply with international data protection standards.

This trial is designed in accordance with the CONSORT guidelines for randomized behavioral and educational interventions. Ethical approval has been obtained from the Research Ethics Committee of Caleb University, Nigeria, and the study will adhere to the principles outlined in the Declaration of Helsinki (1964). Participation is voluntary, and participants may withdraw at any time before data analysis without consequence.

This research is innovative in its use of entertainment-education as a vehicle for improving disease literacy. By evaluating the effect of a medical TV drama on public knowledge of NCC, the study aims to provide evidence for scalable, cost-effective, and culturally adaptable strategies for health communication in resource-limited settings. The findings are expected to contribute to global public health education efforts, particularly those addressing neglected parasitic diseases and preventable causes of epilepsy.

02

Conditions studied

  • Neurocysticercosis
  • Health Literacy
  • Epilepsy
03

In context

Neurocysticercosis

21 studies on the registry are indexed under Neurocysticercosis; 5 are open to participants now.

This study's planned enrollment of 60 is below the median of 107 across 13 interventional studies indexed under Neurocysticercosis.

Browse Neurocysticercosis studies →

Lead sponsor

Cephas Health Research Initiative Inc, Ibadan, Nigeria is the lead sponsor of 2 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 18 to 35 years
  • Proficient in English (reading and comprehension)
  • Has access to a stable internet connection
  • Possesses a screen-enabled device (e.g., smartphone, tablet, or computer)
  • Has access to the Netflix streaming platform

Exclusion criteria

Exclusion Criteria:

  • Has formal education in medical or health sciences
  • Has a prior diagnosis of neurocysticercosis (NCC)
  • Has previously participated in any NCC-related health literacy or awareness program
  • Lacks access to the Netflix movie platform
  • Below 18 years or above 35 years of age
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Intervention (House M.D. Episode)

    Participants in this arm will watch a selected episode of the medical television drama House M.D. (Season 1, Episode 1), which features a dramatized case of neurocysticercosis. The intervention is designed to provide narrative-based exposure to information relevant to the disease. Participants will complete pre- and post-intervention questionnaires assessing knowledge, motivation, and credibility.

    Behavioral: Medical TV Drama Episode (House M.D.)

  • No intervention
    Control (No Episode)

    Participants in this arm will not receive any exposure to medical television content during the study period. They will complete the same pre- and post-intervention questionnaires as the intervention group, allowing comparison of changes in knowledge, motivation, and credibility.

Interventions

  • BehavioralMedical TV Drama Episode (House M.D.)

    Participants in the experimental group will watch a selected episode of the medical drama House M.D. (Season 1, Episode 1), which includes a dramatized storyline relevant to neurocysticercosis. The episode is intended to deliver narrative-based health education. After viewing, participants will complete post-test questionnaires assessing changes in knowledge, motivation, and credibility compared to pre-test results.

    Also known as: House M.D. Season 1, Episode 1

06

What researchers measure

Primary outcomes

  1. Change in Neurocysticercosis (NCC) Knowledge Score

    Knowledge of neurocysticercosis (NCC) will be assessed using the Neurocysticercosis Knowledge Questionnaire, a 10-item multiple-choice instrument developed for this study. Each correct answer is scored as 1 point, and each incorrect or "I don't know" response is scored as 0 points. The total score represents the sum of correct answers, with a minimum possible score of 0 and a maximum possible score of 10. Higher scores indicate better knowledge of NCC across domains such as cause, transmission, symptoms, prevention, and treatment. The primary outcome is the change in total knowledge score from baseline (pre-test) to immediately post-intervention, compared between the intervention and control groups

    Time frame: Baseline and immediately post-intervention (within 1 hour)

Secondary outcomes

  1. Retention of Neurocysticercosis Knowledge

    Knowledge retention will be assessed using the Neurocysticercosis Knowledge Questionnaire, the same 10-item multiple-choice instrument used at baseline and immediately post-intervention. Each correct answer is scored as 1 point, and incorrect or "I don't know" responses are scored as 0 points. The total score is the sum of correct responses, with a minimum possible score of 0 and a maximum possible score of 10. Higher scores indicate better retention of NCC knowledge. The outcome measure is the change in total knowledge score from baseline (pre-test) to 4 weeks post-intervention, as well as between-group differences in retained knowledge over time.

    Time frame: 4 weeks post-intervention.

  2. Perceived Credibility of the Medical TV Drama

    Perceived credibility of the medical TV drama as a health information source will be measured using the Perceived Credibility of Health Media Scale, a 5-item Likert-type scale adapted for this study. Each item is rated from 1 ("Strongly Disagree") to 5 ("Strongly Agree"), assessing dimensions such as trustworthiness, accuracy, and believability of the episode's medical content. Scores for all items will be summed to produce a total credibility score, with a minimum possible score of 5 and a maximum possible score of 25. Higher scores indicate greater perceived credibility and trust in the medical TV drama as a reliable health education resource. The outcome measure is the mean total credibility score immediately following the intervention, compared between the intervention and control groups.

    Time frame: Immediately post-intervention (within 1 hour).

  3. Motivation to Seek Further Health Information

    Participants' motivation to seek additional information about neurocysticercosis (NCC) will be assessed using the Motivation to Seek Health Information Scale, a single-item 5-point Likert-type measure adapted for this study. Participants will rate their likelihood of looking for more information about NCC following the intervention, with response options ranging from 1 ("Not at all likely") to 5 ("Extremely likely"). Scores range from 1 to 5, where higher scores indicate greater motivation to seek additional health information. The outcome will be reported as the mean motivation score immediately post-intervention and compared between the intervention and control groups.

    Time frame: Immediately post-intervention (within 1 hour).

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be shared.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2025; primary completion for Feb 2026, 2 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 28, 2025
First posted
Oct 6, 2025
StartEst.
Dec 15, 2025
Primary completionEst.
Feb 15, 2026
CompletionEst.
Apr 15, 2026
Last update
Dec 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07208656
Lead sponsor
Cephas Health Research Initiative Inc, Ibadan, Nigeria
Responsible party
Emeka Okeke (Dr., Cephas Health Research Initiative Inc, Ibadan, Nigeria) — Principal investigator
First posted
Oct 6, 2025
Start date
Dec 15, 2025 (estimated)
Primary completion
Feb 15, 2026 (estimated)
Completion
Apr 15, 2026 (estimated)
Last update
Dec 4, 2025

Study contacts

Kehinde Kanmodi, PhD
Contact
kanmodikehinde@yahoo.com
+15059006972
Emeka Okeke, PhD
Contact
konebemeka@gmail.com
+447767635349

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion